Non-Viral Drug Delivery Systems Industry Forecast to Hit $16.72 Billion by 2029 With a Strong 14.2% CAGR

Unlock Global Insights – Save 20% on Market Reports with Code ONLINE20

What Is The Future Market Size Estimation For The Non-Viral Drug Delivery Systems Market Covering 2025–2034?

The non-viral drug delivery systems market has witnessed rapid growth in recent years. Its size is expected to expand from $8.6 billion in 2024 to $9.84 billion in 2025, at a compound annual growth rate (CAGR) of 14.4%. This historical growth can be linked to increasing demand for safer gene therapies, rising advancements in nanotechnology, a rise in the prevalence of chronic diseases, increasing focus on personalized medicine, and rising regulatory support for non-viral platforms.

The non-viral drug delivery systems market is projected to experience significant expansion in the coming years, anticipated to reach a valuation of $16.72 billion by 2029, exhibiting a compound annual growth rate (CAGR) of 14.2%. Key drivers for this growth during the forecast period include the increasing adoption of targeted therapies, greater investment in drug delivery research, a growing inclination towards non-invasive treatments, the expanding integration of artificial intelligence, and a rising demand for sustained-release formulations. Noteworthy trends expected over the forecast period encompass progress in nanocarrier technology, the development of advanced biomaterials for improved delivery, breakthroughs in mRNA delivery platforms, the incorporation of smart drug delivery devices, and enhancements in gene editing delivery methods.

Unlock Your Free Sample Report for Exclusive Market Data:

https://www.thebusinessresearchcompany.com/sample.aspx?id=24628&type=smp

Which Major Market Drivers Are Shaping The Future Of The Non-Viral Drug Delivery Systems Market?

The growing requirement for personalized medicines is projected to boost the expansion of the non-viral drug delivery systems market in the future. This medical strategy customizes treatments based on a patient’s unique genetic profile, way of life, and surroundings. The need for personalized medicine is increasing because it enables more effective therapies by addressing the distinct roots of illness in individual patients. Non-viral systems support personalized medicine through the safe delivery of drugs or genes to cells, thereby minimizing risks and enhancing the accuracy of treatment. As an illustration, in February 2024, the Personalized Medicine Coalition, a US-based non-profit organization, reported that the FDA granted approval to 16 novel personalized therapies for rare diseases in 2023, which signifies a rise from six approvals in 2022. Consequently, the heightened demand for personalized medicines is a key factor propelling the expansion of the non-viral drug delivery systems market.

What Are The Leading Segments Analyzed In The Non-Viral Drug Delivery Systems Market?

The non-viral drug delivery systems market covered in this report is segmented –

1) By Type Of Molecule Delivered: Biologics, Small Molecules

2) By Type Of Biologics Delivered: Ribonucleic Acid (RNA), Deoxyribonucleic Acid (DNA), Proteins or Peptides, Antibodies

3) By End User: Pharmaceutical And Biotechnology Companies, Academic And Research Institutes, Contract Development And Manufacturing Organizations (CDMOs), Hospitals And Clinics

Subsegments:

1) By Biologics: Peptides, Proteins, Monoclonal Antibodies, RNA-based Therapeutics, DNA-based Therapies

2) By Small Molecules: Chemotherapeutics, Anti-inflammatories, Antivirals, Antibiotics, Hormonal Drugs

What Long-Term Trends Will Shape The Future Growth Of The Non-Viral Drug Delivery Systems Industry?

Leading companies within the non-viral drug delivery system market are concentrating on advanced technologies, such as pre-optimized ionizable lipid mix systems, to streamline the creation and delivery of RNA-based therapeutics. A pre-optimized ionizable lipid mix system functions as a formulation technology that enables the efficient encapsulation of RNA molecules into lipid nanoparticles, ensuring robust stability, payload protection, and targeted delivery for gene-based drug applications. For instance, in September 2024, Cytiva, a US-based biotechnology company, introduced an RNA delivery LNP kit compatible with its NanoAssemblr Ignite and Ignite+ platforms. This system includes a ready-to-use ionizable lipid mix that allows for rapid screening of RNA payloads and effective delivery validation, particularly relevant for infectious disease vaccine development. It integrates smoothly with automated microfluidic platforms, supports scalable manufacturing through GMP-grade components, and provides protocols and proof-of-concept data to guide users from early discovery to clinical evaluation.

Who Are The Key Multinational Companies Dominating The Non-Viral Drug Delivery Systems Market?

Major companies operating in the non-viral drug delivery systems market are Evonik Industries AG, Cytiva, Arcturus Therapeutics Holdings Inc., CureVac N.V., PolyPid Ltd, Ethris GmbH, Entos Pharmaceuticals Inc., Liquidia Technologies Inc., ReCode Therapeutics Inc., Enable Injections Inc., GenEdit Inc., N4 Pharma Plc, Hopewell Therapeutics Inc., Tiba Biotech LLC, Vesigen Therapeutics Inc., Carmine Therapeutics Inc., Evox Therapeutics Ltd, InnoCore Pharmaceuticals BV, Nanomerics Ltd, DelSiTech Ltd, Curapath Inc.

Download The Full Report For Exclusive Market Findings:

https://www.thebusinessresearchcompany.com/report/non-viral-drug-delivery-systems-global-market-report

Which Region Shows The Highest Potential For Future Expansion In The Non-Viral Drug Delivery Systems Market?

North America was the largest region in the non-viral drug delivery systems market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the non-viral drug delivery systems market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Request A Customized Version Of The Non-Viral Drug Delivery Systems Market Report:

https://www.thebusinessresearchcompany.com/customise?id=24628&type=smp

Browse Through More Reports Similar to the Global Non-Viral Drug Delivery Systems Market 2025, By The Business Research Company

Advanced Drug Delivery Systems Global Market Report 2025

https://www.thebusinessresearchcompany.com/report/advanced-drug-delivery-systems-global-market-report

Electronic Drug Delivery Systems Global Market Report 2025

https://www.thebusinessresearchcompany.com/report/electronic-drug-delivery-systems-global-market-report

Pharmaceutical Drug Delivery Global Market Report 2025

https://www.thebusinessresearchcompany.com/report/pharmaceutical-drug-delivery-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795